RxDoctor Payments Data

Patrick Burke, MD

Hematology · Ann Arbor, MINPI 1164684395

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $5,600 of the $5,867 with a category attached, or 95.5%. Servier Pharmaceuticals LLC accounts for 95.5% of it on its own, with 1 other manufacturer making up the rest.

$5,867in general payments, 2019–2025

Across 2 payments — averaging $2933.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Servier Pharmaceuticals LLC$6K
  • AstraZeneca$267
$629,352in research payments, 2019–2025

Across 42 payments — averaging $14,985 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Otsuka Pharmaceutical Co., Ltd.$217K
  • Novartis$170K
  • AbbVie$120K
  • Takeda Pharmaceuticals U.S.A., Inc.$85K
  • Gilead$33K
  • Taiho Oncology, Inc.$3K

What the payments were for

  • Consulting fees$5,60095%
  • Speaking & faculty fees$2675%

General payments by program year

22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Servier Pharmaceuticals LLC1$5,600
AstraZeneca1$267

How this compares

$5,867 in reported general payments places this provider in the 70th percentile of 50 hematology providers in Michigan.

See all hematology providers in Michigan

Medicare billing

Part B allowed, 2024
$61,655
Medicare patients
108
Services billed
550

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PromactaEltrombopag Olamine13$544,202
VenclextaVenetoclax73$303,275
Posaconazole13$14,755
Voriconazole18$3,807
Imatinib Mesylate15$1,393
MethotrexateMethotrexate Sodium13$721
Acyclovir31$371
Ondansetron Hcl12$170
Levofloxacin16$97
Prednisone11$22

Paid to pharmacies, not to this prescriber.

Other hematology in Ann Arbor

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →